Donor immune cells take on tough viruses in transplant patients
NCT ID NCT05183490
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether specially grown immune cells from a donor can safely help transplant patients fight off viral infections that standard treatments can't control. The cells target Epstein-Barr virus, cytomegalovirus, adenovirus, and BK virus. Up to 36 adults who have had a stem cell or organ transplant will receive an infusion of these cells, and researchers will watch closely for side effects like graft-versus-host disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Rapidly generated virus specific T (R-MVST) cells
- What this could lead to
- If it works, this could offer a new treatment option for transplant patients with viral infections that don't respond to standard care.
- What could go wrong
- This is a very early Phase 1 trial with only 36 participants, focused on safety. The treatment may cause serious side effects like graft-versus-host disease, and it's too soon to know if it effectively controls infections.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADENOVIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can cord blood t cells be trained to stop viral infections after transplant?
- Can immune cells predict herpesvirus danger in transplant patients?
- Can a new IV antiviral tame two stubborn viruses?
- Can a new immune drug outsmart Hard-to-Treat tumors?
- Can specially grown immune cells from donors beat viruses that won't go away?
- A new drug combo may shield kidney transplant patients from a common viral threat